Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

TLRY vs CGC vs CRON vs ACB vs SMG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TLRY
Tilray Brands, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$660M
5Y Perf.-42.5%
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$122M
5Y Perf.-99.3%
CRON
Cronos Group Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$981M
5Y Perf.-60.6%
ACB
Aurora Cannabis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$195M
5Y Perf.-97.6%
SMG
The Scotts Miracle-Gro Company

Agricultural Inputs

Basic MaterialsNYSE • US
Market Cap$3.62B
5Y Perf.-56.3%

TLRY vs CGC vs CRON vs ACB vs SMG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TLRY logoTLRY
CGC logoCGC
CRON logoCRON
ACB logoACB
SMG logoSMG
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericAgricultural Inputs
Market Cap$660M$122M$981M$195M$3.62B
Revenue (TTM)$1.17B$294M$193M$361M$3.35B
Net Income (TTM)$-2.95B$-327M$-9M$41M$90M
Gross Margin28.0%22.8%32.5%62.7%31.0%
Operating Margin-266.0%-24.1%-1.5%13.3%11.7%
Forward P/E34.3x164.2x14.2x
Total Debt$451M$348M$2M$104M$2.38B
Cash & Equiv.$304M$114M$792M$184M$37M

TLRY vs CGC vs CRON vs ACB vs SMGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TLRY
CGC
CRON
ACB
SMG
StockMay 20May 26Return
Tilray Brands, Inc. (TLRY)10057.5-42.5%
Canopy Growth Corpo… (CGC)1000.7-99.3%
Cronos Group Inc. (CRON)10039.4-60.6%
Aurora Cannabis Inc. (ACB)1002.4-97.6%
The Scotts Miracle-… (SMG)10043.7-56.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: TLRY vs CGC vs CRON vs ACB vs SMG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRON and ACB are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Aurora Cannabis Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. SMG and TLRY also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
TLRY
Tilray Brands, Inc.
The Momentum Pick

TLRY is the clearest fit if your priority is momentum.

  • +12.1% vs ACB's -25.3%
Best for: momentum
CGC
Canopy Growth Corporation
The Healthcare Pick

Among these 5 stocks, CGC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
CRON
Cronos Group Inc.
The Income Pick

CRON has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.

  • beta 0.98
  • Rev growth 64.4%, EPS growth -100.0%, 3Y rev CAGR 30.6%
  • 14.6% 10Y total return vs TLRY's -74.7%
  • Lower volatility, beta 0.98, Low D/E 0.1%, current ratio 19.59x
Best for: income & stability and growth exposure
ACB
Aurora Cannabis Inc.
The Quality Compounder

ACB is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 11.2% margin vs TLRY's -252.6%
  • 5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%
Best for: quality and efficiency
SMG
The Scotts Miracle-Gro Company
The Value Play

SMG ranks third and is worth considering specifically for value and dividends.

  • Lower P/E (14.2x vs 164.2x)
  • 4.2% yield; the other 4 pay no meaningful dividend
Best for: value and dividends
See the full category breakdown
CategoryWinnerWhy
GrowthCRON logoCRON64.4% revenue growth vs CGC's -9.5%
ValueSMG logoSMGLower P/E (14.2x vs 164.2x)
Quality / MarginsACB logoACB11.2% margin vs TLRY's -252.6%
Stability / SafetyCRON logoCRONBeta 0.98 vs TLRY's 2.03, lower leverage
DividendsSMG logoSMG4.2% yield; the other 4 pay no meaningful dividend
Momentum (1Y)TLRY logoTLRY+12.1% vs ACB's -25.3%
Efficiency (ROA)ACB logoACB5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%

TLRY vs CGC vs CRON vs ACB vs SMG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TLRYTilray Brands, Inc.
FY 2025
Cannabis Segment
36.1%$331M
Distribution Revenue
29.6%$271M
Beverage Alcohol Business
27.7%$253M
Wellness Business
6.6%$60M
CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0
CRONCronos Group Inc.
FY 2025
Cannabis Flower
74.0%$108M
Cannabis Extracts
25.7%$38M
Product and Service, Other
0.3%$411,000
ACBAurora Cannabis Inc.

Segment breakdown not available.

SMGThe Scotts Miracle-Gro Company
FY 2025
Other Segments
60.5%$254M
Hawthorne
39.5%$166M

TLRY vs CGC vs CRON vs ACB vs SMG — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTLRYLAGGINGSMG

Income & Cash Flow (Last 12 Months)

ACB leads this category, winning 3 of 6 comparable metrics.

SMG is the larger business by revenue, generating $3.4B annually — 17.3x CRON's $193M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to TLRY's -2.5%. On growth, CRON holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…SMG logoSMGThe Scotts Miracl…
RevenueTrailing 12 months$1.2B$294M$193M$361M$3.4B
EBITDAEarnings before interest/tax-$3.0B-$32M-$810,000$71M$466M
Net IncomeAfter-tax profit-$2.9B-$327M-$9M$41M$90M
Free Cash FlowCash after capex-$94M-$86M-$163,766-$31M$358M
Gross MarginGross profit ÷ Revenue+28.0%+22.8%+32.5%+62.7%+31.0%
Operating MarginEBIT ÷ Revenue-2.7%-24.1%-1.5%+13.3%+11.7%
Net MarginNet income ÷ Revenue-2.5%-111.0%-4.9%+11.2%+2.7%
FCF MarginFCF ÷ Revenue-8.1%-29.3%-0.1%-8.7%+10.7%
Rev. Growth (YoY)Latest quarter vs prior year+3.0%+20.9%+2.0%+6.8%-15.0%
EPS Growth (YoY)Latest quarter vs prior year+70.7%+83.8%-100.0%-94.5%-78.5%
ACB leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

TLRY leads this category, winning 2 of 5 comparable metrics.

At 25.3x trailing earnings, SMG trades at a 85% valuation discount to ACB's 164.2x P/E. On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than SMG's 13.8x.

MetricTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…SMG logoSMGThe Scotts Miracl…
Market CapShares × price$660M$122M$981M$195M$3.6B
Enterprise ValueMkt cap + debt − cash$806M$293M$190M$136M$6.0B
Trailing P/EPrice ÷ TTM EPS-0.17x-0.28x164.21x25.25x
Forward P/EPrice ÷ next-FY EPS est.34.27x14.23x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple6.73x13.75x
Price / SalesMarket cap ÷ Revenue0.59x0.62x5.07x0.77x1.06x
Price / BookPrice ÷ Book value/share0.25x0.34x0.90x0.43x
Price / FCFMarket cap ÷ FCF13.22x
TLRY leads this category, winning 2 of 5 comparable metrics.

Profitability & Efficiency

ACB leads this category, winning 4 of 9 comparable metrics.

ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-137 for TLRY. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs TLRY's 4/9, reflecting strong financial health.

MetricTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…SMG logoSMGThe Scotts Miracl…
ROE (TTM)Return on equity-136.5%-43.1%-0.9%+7.2%
ROA (TTM)Return on assets-100.6%-29.5%-0.8%+5.2%+2.9%
ROICReturn on invested capital-66.2%-10.2%-0.8%+0.7%+13.3%
ROCEReturn on capital employed-78.1%-12.4%-0.3%+0.7%+17.4%
Piotroski ScoreFundamental quality 0–945677
Debt / EquityFinancial leverage0.22x0.72x0.00x0.17x
Net DebtTotal debt minus cash$147M$235M-$790M-$80M$2.3B
Cash & Equiv.Liquid assets$304M$114M$792M$184M$37M
Total DebtShort + long-term debt$451M$348M$2M$104M$2.4B
Interest CoverageEBIT ÷ Interest expense-89.43x-7.79x6.27x3.08x
ACB leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TLRY leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in TLRY five years ago would be worth $3,498 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, TLRY leads with a +1209.3% total return vs ACB's -25.3%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs CGC's -55.9% — a key indicator of consistent wealth creation.

MetricTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…SMG logoSMGThe Scotts Miracl…
YTD ReturnYear-to-date-41.8%-5.0%-4.8%-21.0%+6.1%
1-Year ReturnPast 12 months+1209.3%-12.4%+38.9%-25.3%+20.7%
3-Year ReturnCumulative with dividends+103.6%-91.4%+29.1%-47.2%-3.2%
5-Year ReturnCumulative with dividends-65.0%-99.6%-66.6%-96.1%-69.1%
10-Year ReturnCumulative with dividends-74.7%-94.3%+1457.6%-92.0%+34.9%
CAGR (3Y)Annualised 3-year return+26.7%-55.9%+8.9%-19.2%-1.1%
TLRY leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CRON and SMG each lead in 1 of 2 comparable metrics.

CRON is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SMG currently trades 86.2% from its 52-week high vs TLRY's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…SMG logoSMGThe Scotts Miracl…
Beta (5Y)Sensitivity to S&P 5002.03x1.90x0.98x1.81x1.10x
52-Week HighHighest price in past year$15.70$2.38$3.43$6.67$72.35
52-Week LowLowest price in past year$0.35$0.84$1.84$3.07$52.00
% of 52W HighCurrent price vs 52-week peak+36.1%+47.5%+74.9%+51.4%+86.2%
RSI (14)Momentum oscillator 0–10037.952.949.352.248.9
Avg Volume (50D)Average daily shares traded4.7M10.4M1.4M979K938K
Evenly matched — CRON and SMG each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: TLRY as "Hold", CGC as "Hold", CRON as "Hold", ACB as "Hold", SMG as "Buy". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -10.5% for CRON (target: $2). SMG is the only dividend payer here at 4.21% yield — a key consideration for income-focused portfolios.

MetricTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…SMG logoSMGThe Scotts Miracl…
Analyst RatingConsensus buy/hold/sellHoldHoldHoldHoldBuy
Price TargetConsensus 12-month target$10.00$14.47$2.30$5.92$72.00
# AnalystsCovering analysts2026151417
Dividend YieldAnnual dividend ÷ price+4.2%
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS$2.63
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.0%0.0%+0.5%
Insufficient data to determine a leader in this category.
Key Takeaway

ACB leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 2 (Valuation Metrics, Total Returns). 1 tied.

Best OverallTilray Brands, Inc. (TLRY)Leads 2 of 6 categories
Loading custom metrics...

TLRY vs CGC vs CRON vs ACB vs SMG: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TLRY or CGC or CRON or ACB or SMG a better buy right now?

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). The Scotts Miracle-Gro Company (SMG) offers the better valuation at 25. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate The Scotts Miracle-Gro Company (SMG) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TLRY or CGC or CRON or ACB or SMG?

On trailing P/E, The Scotts Miracle-Gro Company (SMG) is the cheapest at 25.

3x versus Aurora Cannabis Inc. at 164. 2x. On forward P/E, The Scotts Miracle-Gro Company is actually cheaper at 14. 2x.

03

Which is the better long-term investment — TLRY or CGC or CRON or ACB or SMG?

Over the past 5 years, Tilray Brands, Inc.

(TLRY) delivered a total return of -65. 0%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus CGC's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TLRY or CGC or CRON or ACB or SMG?

By beta (market sensitivity over 5 years), Cronos Group Inc.

(CRON) is the lower-risk stock at 0. 98β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 107% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — TLRY or CGC or CRON or ACB or SMG?

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: The Scotts Miracle-Gro Company grew EPS 504. 9% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TLRY or CGC or CRON or ACB or SMG?

The Scotts Miracle-Gro Company (SMG) is the more profitable company, earning 4.

3% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMG leads at 10. 5% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TLRY or CGC or CRON or ACB or SMG more undervalued right now?

On forward earnings alone, The Scotts Miracle-Gro Company (SMG) trades at 14.

2x forward P/E versus 34. 3x for Cronos Group Inc. — 20. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CGC: 1180. 5% to $14. 47.

08

Which pays a better dividend — TLRY or CGC or CRON or ACB or SMG?

In this comparison, SMG (4.

2% yield) pays a dividend. TLRY, CGC, CRON, ACB do not pay a meaningful dividend and should not be held primarily for income.

09

Is TLRY or CGC or CRON or ACB or SMG better for a retirement portfolio?

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TLRY and CGC and CRON and ACB and SMG?

These companies operate in different sectors (TLRY (Healthcare) and CGC (Healthcare) and CRON (Healthcare) and ACB (Healthcare) and SMG (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TLRY is a small-cap quality compounder stock; CGC is a small-cap quality compounder stock; CRON is a small-cap high-growth stock; ACB is a small-cap high-growth stock; SMG is a small-cap income-oriented stock. SMG pays a dividend while TLRY, CGC, CRON, ACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TLRY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen
Stocks Like

CRON

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 100%
  • Gross Margin > 19%
Run This Screen
Stocks Like

ACB

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Stocks Like

SMG

Income & Dividend Stock

  • Sector: Basic Materials
  • Market Cap > $100B
  • Gross Margin > 18%
  • Dividend Yield > 1.6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform TLRY and CGC and CRON and ACB and SMG on the metrics below

Revenue Growth>
%
(TLRY: 3.0% · CGC: 20.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.